OA11964A - Pharmaceutical complex. - Google Patents

Pharmaceutical complex. Download PDF

Info

Publication number
OA11964A
OA11964A OA1200100328A OA1200100328A OA11964A OA 11964 A OA11964 A OA 11964A OA 1200100328 A OA1200100328 A OA 1200100328A OA 1200100328 A OA1200100328 A OA 1200100328A OA 11964 A OA11964 A OA 11964A
Authority
OA
OAPI
Prior art keywords
weight
formulation
daims
ciaimed
complex
Prior art date
Application number
OA1200100328A
Other languages
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11964A publication Critical patent/OA11964A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200100328A 1999-06-29 2000-06-02 Pharmaceutical complex. OA11964A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
OA11964A true OA11964A (en) 2006-04-17

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100328A OA11964A (en) 1999-06-29 2000-06-02 Pharmaceutical complex.

Country Status (44)

Country Link
US (2) US6713461B1 (es)
EP (1) EP1189640B1 (es)
JP (2) JP4454900B2 (es)
KR (1) KR20020015067A (es)
CN (1) CN1198654C (es)
AP (1) AP2001002369A0 (es)
AR (1) AR033337A1 (es)
AT (1) ATE290884T1 (es)
AU (1) AU770169B2 (es)
BG (1) BG106151A (es)
BR (1) BR0011845A (es)
CA (1) CA2376847C (es)
CO (1) CO5170494A1 (es)
CZ (1) CZ20014572A3 (es)
DE (1) DE60018744T2 (es)
DZ (1) DZ3320A1 (es)
EA (1) EA003908B1 (es)
EC (1) ECSP003551A (es)
EE (1) EE200100697A (es)
ES (1) ES2235879T3 (es)
GB (1) GB9915231D0 (es)
GE (1) GEP20043377B (es)
GT (1) GT200000102A (es)
HR (1) HRP20010951A2 (es)
HU (1) HUP0201629A3 (es)
IL (1) IL146341A0 (es)
IS (1) IS6163A (es)
MA (1) MA26801A1 (es)
MX (1) MXPA01013274A (es)
NO (1) NO20016430L (es)
NZ (1) NZ515235A (es)
OA (1) OA11964A (es)
PA (1) PA8496801A1 (es)
PE (1) PE20010346A1 (es)
PL (1) PL352902A1 (es)
SK (1) SK18932001A3 (es)
SV (1) SV2002000112A (es)
TN (1) TNSN00142A1 (es)
TR (1) TR200103827T2 (es)
UA (1) UA66932C2 (es)
UY (1) UY26224A1 (es)
WO (1) WO2001000243A1 (es)
YU (1) YU87501A (es)
ZA (1) ZA200110454B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2495864C (en) * 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU212730B (en) 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
PL170330B1 (pl) 1990-10-15 1996-11-29 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
EP0687174B1 (en) 1993-03-05 2001-06-13 Hexal Ag Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
FI955320A7 (fi) 1994-03-07 1995-11-24 Univ Michigan Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
PL337803A1 (en) 1997-07-03 2000-09-11 Pfizer Pharmaceutic agents containing eletriptane hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
US6713461B1 (en) 2004-03-30
HUP0201629A2 (hu) 2003-03-28
GT200000102A (es) 2001-12-14
EA200101106A1 (ru) 2002-06-27
US20040186076A1 (en) 2004-09-23
TNSN00142A1 (fr) 2005-11-10
GB9915231D0 (en) 1999-09-01
JP2003503364A (ja) 2003-01-28
ECSP003551A (es) 2002-01-25
NZ515235A (en) 2003-08-29
CA2376847A1 (en) 2001-01-04
EE200100697A (et) 2003-02-17
SV2002000112A (es) 2002-02-05
JP2006257091A (ja) 2006-09-28
AP2001002369A0 (en) 2001-12-31
CN1198654C (zh) 2005-04-27
PL352902A1 (en) 2003-09-22
UA66932C2 (en) 2004-06-15
JP4454900B2 (ja) 2010-04-21
PE20010346A1 (es) 2001-03-26
CZ20014572A3 (cs) 2002-08-14
TR200103827T2 (tr) 2002-05-21
CN1359303A (zh) 2002-07-17
CA2376847C (en) 2007-09-25
ZA200110454B (en) 2002-12-20
DE60018744T2 (de) 2006-05-18
BR0011845A (pt) 2002-03-05
BG106151A (en) 2002-05-31
AU770169B2 (en) 2004-02-12
ES2235879T3 (es) 2005-07-16
YU87501A (sh) 2004-05-12
ATE290884T1 (de) 2005-04-15
IL146341A0 (en) 2002-07-25
AR033337A1 (es) 2003-12-17
GEP20043377B (en) 2004-04-13
HRP20010951A2 (en) 2005-04-30
MA26801A1 (fr) 2004-12-20
EP1189640B1 (en) 2005-03-16
SK18932001A3 (sk) 2002-09-10
EP1189640A1 (en) 2002-03-27
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
NO20016430L (no) 2002-02-26
UY26224A1 (es) 2001-01-31
DE60018744D1 (de) 2005-04-21
KR20020015067A (ko) 2002-02-27
DZ3320A1 (fr) 2001-01-04
HUP0201629A3 (en) 2003-11-28
WO2001000243A1 (en) 2001-01-04
CO5170494A1 (es) 2002-06-27
PA8496801A1 (es) 2002-02-21
NO20016430D0 (no) 2001-12-28
MXPA01013274A (es) 2002-06-04
AU4774100A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
AU712546B2 (en) Inclusion complex containing indole selective serotonin agonist
US20070196472A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
HUT77391A (hu) A droloxifen alkalmazása keringési megbetegedésekben
JPH05504783A (ja) 水溶解性の高いシクロデキストリン誘導体組成物及びその用途
WO1997003662A1 (en) Pharmaceutical composition of l-dopa ethyl ester
EP1189640B1 (en) Complex of eletriptan and sulphobutylether-cyclodextrin and its use for the treatment of migraine
AU781828B2 (en) Dosing regimens for lasofoxifene
RU2367442C2 (ru) Способ нормализации мочеиспускания при нарушении функции почек
JPH04210924A (ja) カルシトニンの経口投与用の製薬組成物及び投薬形態
JP2005515982A (ja) ２−ヒドロキシプロピル−β−シクロデキストリンによるタキソールの包接錯体
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
JP2011246497A (ja) イオン交換樹脂を使用する経口キノロン液状製剤の味覚マスキング
JP4965784B2 (ja) バイオアベイラビリティの向上した麦角アルカロイドの徐放性医薬組成物の製造法及びその組成物
JPH10265495A (ja) フルオロプロゲステロン誘導体包接化合物
JPS58116423A (ja) メタノプロスタサイクリン製剤組成物
CN121081666A (zh) 一种卡普瑞林制剂及其制备方法与应用
JPWO2005058878A1 (ja) 月経困難症の予防および／または治療剤
JPS63130534A (ja) 胃腸病の治療用組成物
CN1225018A (zh) 含有吲哚选择性的5－羟色胺激动剂的包合配合物
JP2003261448A (ja) 抗腫瘍剤
JPH11116471A (ja) 乳癌の予防のためのドロロキシフェン